Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
ten23 health’s new combination of pharma development services with clinical & commercial fill/finish services will offer customers an end-to-end capabilities.
October 25, 2021
By: Tim Wright
Editor-in-Chief, Contract Pharma
ten23 health, a global contract development and manufacturing organization (CDMO), has acquired swissfillon AG, located in Visp, Switzerland. swissfillon will join ten23 to enhance the companies’ integrated offering of drug product development services and fill-finish manufacturing to their combined group of customers. swissfillon is a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices. The company, which was founded in 2013, employs over 50 people and is a specialized player in the global CDMO market. swissfillon’s operations have been approved by Swissmedic for the European market since 2018 and by the FDA for the U.S. market since 2019. The company currently supports various clinical and early commercial customer programs. The combined business of ten23 health and swissfillon will provide an integrated offering for sterile drug product development and manufacturing of biologics, challenging molecules and dosage forms. swissfillon will continue to operate under its brand, which stands for first-class Swiss quality and excellent know-how. Prof. Dr. Hanns-Christian Mahler will serve as CEO of the combined entities under the ten23 health umbrella. Daniel Kehl, founder of swissfillon, will remain with the business in a key leadership role and will help to lead ten23’s new infrastructure engineering projects that are of great strategic importance for the further development of the combined offering. swissfillon manufactures sterile dosage forms—usually a syringe, cartridge or vial—which allow a drug substance to be administered to a patient to meet the increasing market demand for complex products and patient centric application forms. Biologics are sensitive to temperature and manufacturing stresses and are often developed for applications such as intraocular or subcutaneous injection, requiring specific expertise in both development and manufacturing. swissfillon´s latest generation fill/finish technologies allow very small quantities to be filled, while minimizing losses of these very expensive drugs. swissfillon also has a specialized expertise in bubble-free filling, ensuring dose precision and product safety, specifically relevant for subcutaneous and intravitreal injetions. Last year, swissfillon also supplied 0.8 million aseptically filled transport media in syringes for the Swiss army pharmacy’s COVID-19 PCR test kit related to the urgent provision of testing capabilities. “We look forward to join ten23 health’s world-class team. There is a great strategic fit between our profound expertise in sterile drug product manufacturing for complex pharmaceuticals and ten23 health’s focus on the development and manufacturing of injectable treatments,” said Daniel Kehl, current CEO of swissfillon. “By pooling our profound expertise, we will be able to further expand our market position for injectable treatments. The swissfillon team looks forward to continue advancing under the ten23 health umbrella and providing our combined group of customers with excellent support and customizable solutions.” Hanns-Christian Mahler, CEO of ten23 health, said, “Sterile fill and finish services are expected to experience significant growth over the coming years. The rising demand is driven by expanded drug development pipelines, incorporating more complex, large-molecule products and therapies that require specific expertise for both development and sterile production. This is precisely why we expect ten23 health´s services, now including swissfillon, to be in great demand. At ten23 health, we are very pleased that we can now offer this sought-after know-how to biotech startups and pharmaceutical companies from one single source.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !